(36) Other financial assets
Accounting and measurement policies
Other financial assets
This section does not cover the accounting and measurement policies for derivative financial instruments. They are presented separately in Note (39) “Derivative financial instruments”.
Recognition and initial measurement
Financial assets are initially measured at fair value and recognized as of the settlement date. For financial assets not subsequently measured at fair value through profit or loss in subsequent periods, initial measurement also includes directly attributable transaction costs. Any difference between the fair value of a financial instrument on initial recognition (Level 2 and 3) and the transaction price is recognized in income using the straight-line method over the duration.
Detailed information on the measurement methods for financial assets measured at fair value are presented in Note (43) “Information on fair value measurement”.
Classification and subsequent measurement
On initial recognition, financial assets are assigned to one of the following measurement categories which also correspond to the financial instrument classes as defined in IFRS 9:
- subsequent measurement at amortized cost,
- subsequent measurement at fair value through other comprehensive income, or
- subsequent measurement at fair value through profit or loss.
This classification is based on the business model and the structure of contractual payment flows. Financial assets subsequently measured at amortized cost are accounted for using the effective interest method and considering any impairment losses. The procedure for calculating impairment losses is described in Note (42) “Management of financial risks”. Financial assets of this class are held in order to collect their contractual cash flows, which are exclusively principal repayments and interest payments on the outstanding capital amount.
Except for derivative financial instruments with positive market value, the Group only applies subsequent measurement at fair value through profit or loss for debt instruments with contractual properties resulting in cash flows that do not exclusively represent principal repayments and interest payments on the outstanding capital amount. In particular, this includes contingent consideration that was contractually agreed with the acquirer within the context of the disposal of businesses within the meaning of IFRS 3 (see Note (43) “Information on fair value measurement”). The Group does not utilize the option of the subsequent measurement of debt instruments at fair value through profit or loss.
Equity instruments not subject to mandatory subsequent measurement at fair value through profit or loss are measured at fair value through other comprehensive income in subsequent periods and if they are intended to be held for the longer term. Further details on the measurement of equity instruments at fair value are presented in Note (43) “Information on fair value measurement”.
Financial assets are only reclassified in the rare event of the Group changing its business model with regard to the management of financial assets.
Derecognition
Financial assets are derecognized if the claim for compensation is fulfilled by the other counterparty, if there is no longer a reasonable expectation that the counterparty will fulfill its contractual obligations, or if the Group transfers the contractual rights including all material risks and rewards of the financial asset to another counterparty.
Recognition
Measurement effects of debt instruments are reported in the consolidated balance sheet and the consolidated income statement as follows:
Category |
|
Asset type |
|
Impairment losses/reversals of impairment losses |
|
Net gain and net loss on disposal/value adjustments |
|
Foreign currency gains or losses |
|
Interest income or expenses |
|---|---|---|---|---|---|---|---|---|---|---|
Subsequent measurement at amortized cost |
|
Operational |
|
Impairment losses, and reversals of impairment losses of financial assets (net) |
|
Other operating income or other operating expenses |
|
Other operating income or other operating expenses |
|
Financial income and expenses (applying the effective interest method) |
|
Financial |
|
Financial income and expenses |
|
Financial income and expenses |
|
Financial income and expenses |
|
||
Subsequent measurement at fair value through other comprehensive income |
|
Operational |
|
Impairment losses, and reversals of impairment losses of financial assets (net) |
|
Group equity (upon derecognition: reclassification to other operating income or other operating expenses) |
|
Other operating income or other operating expenses |
|
Financial income and expenses |
|
Financial |
|
Financial income and expenses |
|
Group equity (upon derecognition: reclassification to financial income and expenses) |
|
Financial income and expenses |
|
||
Subsequent measurement at fair value through profit or loss |
|
Operational |
|
|
|
Other operating income or other operating expenses |
|
Other operating income or other operating expenses |
|
Financial income and expenses |
|
Financial |
|
|
Financial income and expenses |
|
Financial income and expenses |
|
The recognition of income from the unwinding of discounts and income and expenses from interest rate-induced changes in contingent considerations measured at fair value through profit or loss subsequent to initial recognition are reported in financial income and expenses.
The following table provides details on the measurement effects of equity instruments on the consolidated balance sheet and the consolidated income statement:
Category |
|
Asset type |
|
Value adjustments |
|
Foreign currency |
|
Dividend income |
|---|---|---|---|---|---|---|---|---|
Subsequent measurement at fair value through other comprehensive income |
|
Operational |
|
Results recognized directly in equity |
|
Foreign currency gains and losses recognized directly in equity |
|
Other operating income |
|
|
Reclassification of the cumulative results previously recognized directly in equity in the retained earnings when asset is disposed |
|
|
||||
|
Financial |
|
Results recognized directly in equity |
|
Foreign currency gains and losses recognized directly in equity |
|
Financial income |
|
|
|
Reclassification of the cumulative results previously recognized directly in equity in the retained earnings when asset is disposed |
|
|
||||
Subsequent measurement at fair value through profit or loss |
|
Operational |
|
Other operating income or other operating expenses |
|
Other operating income or other operating expenses |
|
Other operating income |
|
Financial |
|
Financial income and expenses |
|
Financial income and expenses |
|
Financial income |
At the reporting date, other financial assets were composed as follows:
|
|
Dec. 31, 2023 |
|
Dec. 31, 2022 |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
€ million |
|
current |
|
non-current |
|
Total |
|
current |
|
non-current |
|
Total |
Subsequent measurement at amortized cost |
|
201 |
|
4 |
|
204 |
|
122 |
|
4 |
|
126 |
Loans against third parties |
|
1 |
|
4 |
|
4 |
|
– |
|
4 |
|
4 |
Other |
|
200 |
|
– |
|
200 |
|
122 |
|
– |
|
122 |
Subsequent measurement at fair value through other comprehensive income |
|
198 |
|
644 |
|
842 |
|
80 |
|
517 |
|
597 |
Equity instruments |
|
– |
|
643 |
|
643 |
|
– |
|
516 |
|
516 |
Debt instruments |
|
198 |
|
1 |
|
199 |
|
80 |
|
1 |
|
81 |
Subsequent measurement at fair value through profit and loss |
|
63 |
|
333 |
|
396 |
|
66 |
|
436 |
|
502 |
Contingent consideration |
|
– |
|
125 |
|
125 |
|
14 |
|
235 |
|
250 |
Other debt instruments |
|
33 |
|
161 |
|
194 |
|
28 |
|
154 |
|
182 |
Derivatives without a hedging relationship (financial transactions) |
|
27 |
|
– |
|
27 |
|
16 |
|
– |
|
16 |
Derivatives without a hedging relationship (operational) |
|
3 |
|
47 |
|
50 |
|
7 |
|
46 |
|
53 |
Derivatives with a hedging relationship (operational) |
|
37 |
|
– |
|
37 |
|
53 |
|
– |
|
53 |
Financial assets |
|
499 |
|
981 |
|
1,480 |
|
321 |
|
957 |
|
1,278 |
The increase in other current financial assets with subsequent measurement at amortized cost related to deposits with banks. Debt instruments with subsequent measurement at fair value through other comprehensive income increased in the year under review due to the purchase of commercial papers.
As in the previous year, contingent consideration primarily included claims arising from the sale of the biosimilars business to Fresenius SE & Co. KGaA, Bad Homburg vor der Höhe, in 2017. The reduction in contingent consideration was mainly attributable to payments received.
Equity interests with subsequent measurement at fair value through other comprehensive income mainly related to shares in the following companies in particular:
€ million |
|
Fair value as of Dec. 31, 2023 |
|
Fair Value: hierarchy level IFRS 13 |
|
Fair value as of Dec. 31, |
|
Fair Value: hierarchy level IFRS 13 |
|---|---|---|---|---|---|---|---|---|
M Ventures portfolio |
|
436 |
|
|
|
422 |
|
|
DNA Script S.A.S., France |
|
<50 |
|
Level 3 |
|
<50 |
|
Level 3 |
Vera Therapeutics, Inc., United States |
|
<50 |
|
Level 1 |
|
<50 |
|
Level 1 |
Precigen, Inc., United States |
|
<50 |
|
Level 1 |
|
<50 |
|
Level 1 |
Artios Pharma Limited, UK |
|
<25 |
|
Level 3 |
|
<50 |
|
Level 3 |
Wiliot Ltd., Israel |
|
<25 |
|
Level 3 |
|
<25 |
|
Level 3 |
Celestial AI Inc., United States |
|
<25 |
|
Level 3 |
|
<15 |
|
Level 3 |
Mosa Meat B.V., Netherlands |
|
<25 |
|
Level 3 |
|
<50 |
|
Level 3 |
Storm Therapeutics Limited, UK |
|
<15 |
|
Level 3 |
|
<15 |
|
Level 3 |
Asceneuron SA, Switzerland |
|
<15 |
|
Level 3 |
|
<15 |
|
Level 3 |
ElectronInks Inc., United States |
|
<15 |
|
Level 3 |
|
<15 |
|
Level 3 |
Formo Bio GmbH, Germany |
|
<15 |
|
Level 3 |
|
<15 |
|
Level 3 |
Nouscom AG, Switzerland |
|
<15 |
|
Level 3 |
|
- |
|
- |
Plexium Inc., United States |
|
<15 |
|
Level 3 |
|
<15 |
|
Level 3 |
Other (notation in an active market) |
|
1 |
|
Level 1 |
|
4 |
|
Level 1 |
Other (no notation in an active market) |
|
200 |
|
Level 3 |
|
181 |
|
Level 3 |
|
|
|
|
|
|
|
|
|
Other minority interests |
|
207 |
|
|
|
94 |
|
|
MoonLake Immunotherapeutics Ltd., Cayman Islands |
|
152 |
|
Level 1 |
|
– |
|
Level 1 |
MoonLake Immunotherapeutics AG, Switzerland |
|
0 |
|
Level 1 |
|
34 |
|
Level 1 |
IDRX, Inc., United States |
|
17 |
|
Level 3 |
|
10 |
|
Level 3 |
InfraServ GmbH & Co. Wiesbaden KG, Germany |
|
13 |
|
Level 3 |
|
22 |
|
Level 3 |
Telios Pharma, Inc., United States |
|
9 |
|
Level 3 |
|
10 |
|
Level 3 |
Other (notation in an active market) |
|
2 |
|
Level 1 |
|
– |
|
Level 1 |
Other (no notation in an active market) |
|
14 |
|
Level 3 |
|
18 |
|
Level 3 |
|
|
|
|
|
|
|
|
|
Total |
|
643 |
|
|
|
516 |
|
|